Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03457948
Title Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

neuroendocrine tumor

Therapies

Pembrolizumab

Pembrolizumab + Yttrium-90 microsphere therapy

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.